Clinical trial
Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.
NCT01271309 is registered in ClinicalTrials.gov with IRCCS Multimedica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Migratory and Angiogenic Dysfunction of Circulating CD133 Stem Cells: a New Prognostic Marker in Myocardial Ischemia.
- Lead sponsor
- IRCCS Multimedica
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- July 31, 2013
- Enrollment
- 170 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.